Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764535 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL231375 | 0.88 | OPRD1 (0.67) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL17283182 | 0.86 | OPRD1 (0.50) | OPRD1ATMOPRM1KCNH2OPRK1 | |
| SCHEMBL17283187 | 0.86 | OPRD1 (0.63) | OPRD1OPRM1OPRK1 | |
| SCHEMBL2751728 | 0.83 | OPRD1 (0.72) | OPRD1ATMOPRM1KCNH2OPRK1 | |
| SCHEMBL13771717 | 0.81 | OPRD1 (0.66) | OPRD1ATMOPRM1KCNH2OPRK1 | |
| SCHEMBL4825406 | 0.79 | OPRD1 (0.67) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL9925784 | 0.79 | OPRD1 (0.67) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL14108184 | 0.78 | OPRD1 (0.66) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL84143 | 0.78 | OPRD1 (0.66) | OPRD1OPRM1KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9314463-B2 | Oligomer-diarylpiperazine conjugates | NEKTAR THERAPEUTICS (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | BIRC5, MTX2, IAPP | OPRD1 2294/4885ATM 4872/4885OPRM1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.